Westover Capital Advisors LLC Has $1.43 Million Stock Position in Merck & Co., Inc. $MRK

Westover Capital Advisors LLC lifted its holdings in Merck & Co., Inc. (NYSE:MRK) by 109.6% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 11,842 shares of the company’s stock after buying an additional 6,192 shares during the period. Westover Capital Advisors LLC’s holdings in Merck & Co., Inc. were worth $1,425,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Kingdom Financial Group LLC. purchased a new stake in shares of Merck & Co., Inc. in the fourth quarter worth approximately $25,000. Abound Financial LLC acquired a new position in Merck & Co., Inc. in the 4th quarter valued at approximately $26,000. Prosperity Bancshares Inc purchased a new stake in Merck & Co., Inc. in the 4th quarter worth approximately $26,000. High Note Wealth LLC lifted its position in Merck & Co., Inc. by 58.9% in the 4th quarter. High Note Wealth LLC now owns 294 shares of the company’s stock worth $31,000 after buying an additional 109 shares in the last quarter. Finally, IFC & Insurance Marketing Inc. acquired a new stake in shares of Merck & Co., Inc. during the 4th quarter valued at $31,000. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the stock. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $120.00 price target on shares of Merck & Co., Inc. in a research note on Monday, July 6th. Wells Fargo & Company boosted their target price on Merck & Co., Inc. from $145.00 to $150.00 and gave the company an “overweight” rating in a research note on Wednesday, July 8th. CICC Research assumed coverage on Merck & Co., Inc. in a research report on Wednesday, June 24th. They issued an “outperform” rating and a $138.00 target price on the stock. Wall Street Zen raised Merck & Co., Inc. from a “hold” rating to a “buy” rating in a research report on Sunday. Finally, BMO Capital Markets raised their price target on Merck & Co., Inc. from $135.00 to $142.00 and gave the stock an “outperform” rating in a research note on Monday. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and seven have given a Hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $133.94.

Merck & Co., Inc. Stock Up 2.3%

MRK opened at $123.56 on Thursday. The business has a 50 day moving average price of $119.48 and a 200 day moving average price of $116.72. Merck & Co., Inc. has a twelve month low of $76.66 and a twelve month high of $130.29. The company has a debt-to-equity ratio of 1.02, a quick ratio of 1.06 and a current ratio of 1.30. The firm has a market cap of $305.16 billion, a P/E ratio of 34.80, a price-to-earnings-growth ratio of 3.03 and a beta of 0.19.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings results on Thursday, April 30th. The company reported ($1.28) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.47) by $0.19. The company had revenue of $16.29 billion during the quarter, compared to analysts’ expectations of $15.85 billion. Merck & Co., Inc. had a net margin of 13.59% and a return on equity of 27.55%. The business’s quarterly revenue was up 4.9% compared to the same quarter last year. During the same period in the prior year, the company earned $2.22 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. Research analysts forecast that Merck & Co., Inc. will post 4.35 EPS for the current year.

Merck & Co., Inc. Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, July 8th. Shareholders of record on Monday, June 15th were issued a $0.85 dividend. This represents a $3.40 annualized dividend and a yield of 2.8%. The ex-dividend date of this dividend was Monday, June 15th. Merck & Co., Inc.’s payout ratio is 95.77%.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.